EUVIMEDEUVIMED entdecken
Crossref

Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

Natalya Risinskaya, Sofia Starchenko, Yulia Chabaeva, Abdulpatakh Abdulpatakhov, Ekaterina Kotova, Valeriya Surimova, Dmitry Bessmertnyy, Anastasia Kashlakova, Anastasia Vasileva, Zalina Fidarova, Olga Aleshina, Anna Yushkova und 9 weitere

Targeted Cancer Therapy Connect · 24.03.2026

DOI: 10.69709/tctc.2026.199772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Cancer Therapy Connect, online erschienen am 24.03.2026. Verfasst von Natalya Risinskaya und 20 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The tumor suppressor p53 is a critical regulator of gene expression in cancer, acting through binding to specific p53 response elements (REs). One of key RE rs4590952 is found in the KITLG gene.

Aims

This study aimed to precisely investigate the allelic variants of the SNP rs4590952 within patient groups with acute leukemia and to analyze their association with the disease and response to therapy. A specific objective was to determine the frequency and nature of regions of homozygosity encompassing the KITLG locus.

Methods

The study cohort included: 37 patients with Ph-negative B-ALL, 38 with T-ALL, and 35 with de novo intermediate-risk AML. A reference group of 200 healthy individuals without oncohematological disorders was used for comparison. Chromosomal microarray analysis (CMA) was performed using the CytoScan™ HT-CMA. Statistical analysis was performed using Python 3.12.4 and SAS 9.4.

Results

The allele frequency (AF) of the G allele of rs4590952 was 0.785 in the reference group. Among patients, the AF was 0.833 in T-ALL, 0.757 in B-ALL, and 0.743 in AML. The frequency of copy-neutral loss of heterozygosity (cn-LOH) at 12q21.32, which results in the GG genotype, was significantly higher in the T-ALL group (45%) compared to the reference group (27%) (OR=0.4; 95% CI: 0.2–0.9; p=0.02). A significant association between MRD-positive status and cn-LOH KITLG was found specifically in the T-ALL group (OR=11; 95% CI: 2–62; p=0.005). Cn-LOH KITLG was also significantly associated with poor chemotherapy response in AML (p=0.01). Summary: The GG genotype of the p53 response element in KITLG (rs4590952) frequently arises from acquired cn-LOH at 12q21.32, observed in 45% of T-ALL and 26-27% of other cases. This treatment-response marker, present irrespective of leukemic status, warrants further validation in expanded cohorts.

Zitieren

APA

Risinskaya, N., Starchenko, S., Chabaeva, Y., Abdulpatakhov, A., Kotova, E., Surimova, V., Bessmertnyy, D., Kashlakova, A., Vasileva, A., Fidarova, Z., Aleshina, O., Yushkova, A., Dubova, O., Nikiforova, K., Kapranov, N., Galtseva, I., Ponomareva, A., Kanivets, I., Korostelev, S., …, & Parovichnikova, E. (2026). Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia. Targeted Cancer Therapy Connect. https://doi.org/10.69709/tctc.2026.199772

Vancouver

Risinskaya N, Starchenko S, Chabaeva Y, Abdulpatakhov A, Kotova E, Surimova V, et al. Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia. Targeted Cancer Therapy Connect. 2026. doi:10.69709/tctc.2026.199772

BibTeX
@article{Risinskaya2026,
  author = {Risinskaya, Natalya and Starchenko, Sofia and Chabaeva, Yulia and Abdulpatakhov, Abdulpatakh and Kotova, Ekaterina and Surimova, Valeriya and Bessmertnyy, Dmitry and Kashlakova, Anastasia and Vasileva, Anastasia and Fidarova, Zalina and Aleshina, Olga and Yushkova, Anna and Dubova, Olga and Nikiforova, Kseniya and Kapranov, Nikolay and Galtseva, Irina and Ponomareva, Alina and Kanivets, Ilya and Korostelev, Sergey and Kulikov, Sergey and Parovichnikova, Elena},
  title = {Association of 12q21.32 cn‑LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia},
  journal = {Targeted Cancer Therapy Connect},
  year = {2026},
  doi = {10.69709/tctc.2026.199772}
}
Kostenlos starten →